chartexchange

ImmunityBio Reports Q3 2026 Results: Net Loss of $184. ...

GuruFocus | Nov 9, 2026 8:30 AM EST

Product Revenue Grows 53% Year-Over-Year as ANKTIVA Label Expands and Global Approvals Reach 35 Countries Related Stocks: IBRX ,

Read original article